Designing hypothesis of substituted benzoxazinones as HIV-1 reverse transcriptase inhibitors: QSAR approach

References

• Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984;224:500–503.
   PubMed Web of Science ®Google Scholar
• Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–871.
   PubMed Web of Science ®Google Scholar
• Clercq ED. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 1995;38:2491–2517.
   PubMed Web of Science ®Google Scholar
• Milton J, Slater MJ, Bird AJ, Spinks D, Scott G, Price CE et al. Biaryl acids: Novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2. Bioorg Med Chem Lett 1998;8:2623–2628.
   PubMed Web of Science ®Google Scholar
• Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA et al. L-743, 726 (DMP-266): A novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type-1 reverse transcriptase. Antimicrob Agents Chemother 1995;39:2602–2605.
   PubMed Web of Science ®Google Scholar
• Patel M, McHugh RJ Jr, Cordova BC, Klabe RM, Erickson-Viitanen S, Trainor GL et al. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of efavirenz (SUSTIVA). Bioorg Med Chem Lett 1999;9:3221–3224.
   PubMed Web of Science ®Google Scholar
• Balaji S, Karthikeyan C, Hari Narayana Moorthy NS, Trivedi P., Trivedi, QSAR modeling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors. Bioorg Med Chem Lett 1999;14:6089–6094.
   Google Scholar
• Duchowicz PR, Fernández M, Caballero J, Castro EA, Fernández FM. QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem 2006;14:5876–5889.
   PubMed Web of Science ®Google Scholar
• Leonard JT, Roy K. QSAR by LFER model of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA, and PLS techniques. Bioorg Med Chem 2006;14:1039–1046.
   PubMed Web of Science ®Google Scholar
• Thomas Leonard J, Roy K. Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas. Bioorg Med Chem Lett 2006;16:4467–4474.
   Google Scholar
• Ravichandran V. QSAR based prediction of anti-HCV activity of thiourea derivatives. Mol Simulation 2010;36:878–886.
   Google Scholar
• Barreca ML, Carotti A, Carrieri A, Chimirri A, Monforte AM, Calace MP et al. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). Bioorg Med Chem 1999;7:2283–2292.
   PubMed Web of Science ®Google Scholar
• Ravichandran V, Jain PK, Mourya VK, Agrawal RK. QSAR study on some arylsulfonamides as anti-HIV agents. Med Chem Res 2007;16:342–351.
   Google Scholar
• Ravichandran V, Mourya VK, Agrawal RK. QSAR study of novel 1,1,3-trioxo [1,2,4]-thiadiazine (TTDs) analogues as potent anti-HIV agents. Arkivoc 2007;XIV:204–212.
   Google Scholar
• Ravichandran V, Mourya VK, Agrawal RK. QSAR prediction of HIV–1 reverse transcriptase inhibitory activity of benzoxazinone derivatives. Internet Electron J Mol 2007;6:363–374.
   Google Scholar
• Ravichandran V, Mourya VK, Agrawal RK. QSAR modeling of HIV-1 reverse transcriptase inhibitory activity with PETT derivatives. Digest J Nanomat Biostruct 2008;3:9–17.
   Google Scholar
• Ravichandran V, Mourya VK, Agrawal RK. Prediction of HIV-1 protease inhibitory activity of 4-hydroxy-5,6-dihydropyran-2-ones: QSAR study. J Enzyme Inhib Med Chem 2011;26:288–294.
   PubMed Web of Science ®Google Scholar
• Ravichandran V, Jain A, Mourya VK, Agrawal RK. Prediction of anti-HIV activity and cytotoxicity of pyrimidinyl and triazinyl amines: QSAR study. Chem Pap 2008;62:596–602.
   Google Scholar
• Ravichandran V, Mourya VK, Agrawal RK. Prediction of anti-HIV activity of 1,3-thiazolidin-4-ones: QSAR approach. Digest J Nanomat Biostruct 2008;3:19–31.
   Google Scholar
• Ravichandran V, Jain A, Mourya VK, Agrawal RK. Prediction of HIV-1 protease inhibitory activity of (4-hydroxy-6-phenyl-2-oxo-2H-pyran-3-yl) thiomethanes: QSAR study. Current Trends in Biotech Pharm 2009;3:37–42.
   Google Scholar
• Ravichandran V, Mourya VK, Agrawal RK. QSAR Analysis of benzodithiazines as HIV-1 integrase inhibitors. Asian Pac J Trop Med 2009;2:15–22.
   Google Scholar
• Ravichandran V, Shalini S, Sundram K, Sokkalingam AD. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors. Eur J Med Chem 2010;45:2791–2797.
   Google Scholar
• Sahu KK, Ravichandran V, Jain PK, Sharma S, Mourya VK, Agrawal RK. QSAR analysis of caffeoyl naphthalene sulphonamide derivatives as HIV-1 integrase inhibitors. Med Chem Res 2007;5:418–430.
   Google Scholar
• Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130–4146.
   PubMed Web of Science ®Google Scholar
• Böhm M, St rzebecher J, Klebe G. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 1999;42:458–477.
   PubMed Web of Science ®Google Scholar
• Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D-QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem 2002;45:841–852.
   PubMed Web of Science ®Google Scholar
• Ravichandran V, Prashantha Kumar BR, Sankar S, Agrawal RK. Predicting anti-HIV activity of 1,3,4-thiazolidinone derivatives: 3D-QSAR approach. Eur J Med Chem 2009;44:1180–1187.
   PubMed Web of Science ®Google Scholar
• Pungpo P, Hannongbua S. Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis. J Mol Graph Model 2000;18:581–90, 601.
   PubMed Web of Science ®Google Scholar
• Jayatilleke PR, Nair AC, Zauhar R, Welsh WJ. Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. J Med Chem 2000;43:4446–4451.
   PubMed Web of Science ®Google Scholar
• Ravichandran, V, Prashanthakumar BR, Sankar S, Agrawal RK. Comparative molecular similarity indices analysis for predicting anti-HIV activity of phenyl ethyl thiourea (PET) derivatives. Med Chem Res 2008;17:1–11.
   Web of Science ®Google Scholar
• Debnath AK. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. j Med Chem 1999;42:249–259.
   PubMed Web of Science ®Google Scholar
• Ravichandran V, Agrawal RK. Predicting anti-HIV activity of PETT derivatives: CoMFA approach. Bioorg Med Chem Lett 2007;17:2197–2202.
   PubMed Web of Science ®Google Scholar
• Qin B, Jiang X, Lu H, Tian X, Barbault F, Huang L et al. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem 2010;53:4906–4916.
   PubMed Web of Science ®Google Scholar
• Hu R, Barbault F, Delamar M, Zhang R. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 2009;17:2400–2409.
   PubMed Web of Science ®Google Scholar
• Hu R, Barbault F, Maurel F, Delamar M, Zhang R. Molecular dynamics simulations of 2-amino-6-arylsulphonylbenzonitriles analogues as HIV inhibitors: interaction modes and binding free energies. Chem Biol Drug Des 2010;76:518–526.
   PubMed Web of Science ®Google Scholar
• Teixeira C, Serradji N, Maurel F, Barbault F. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Eur J Med Chem 2009;44:3524–3532.
   PubMed Web of Science ®Google Scholar
• Liu K, Lu H, Hou L, Qi Z, Teixeira C, Barbault F et al. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem 2008;51:7843–7854.
   PubMed Web of Science ®Google Scholar
• Patel M, McHugh RJ Jr, Cordova BC, Klabe RM, Bacheler LT, Erickson-Viitanen S et al.. Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett 2001;11:1943–1945.
   Google Scholar
• Johns BA, Weatherhead JG, Allen SH, Thompson JB, Garvey EP, Foster SA et al. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Bioorg Med Chem Lett 2009;19:1802–1806.
   PubMed Web of Science ®Google Scholar
• Hudson BD, Hyde RM, Rahr E, Wood J. Parameter based methods for compound selection from chemical databases. Quant Struct Act Rel 1996;15:285–289.
   Google Scholar
• Lather V, Fernandes MX. QSAR models for prediction of PPARδ agonistic activity of indanylacetic acid derivatives. QSAR Comb Sci 2009;28:447–457.
   Google Scholar
• Guyon A., Elisseeff, An introduction to variable and feature selection. J Mach Learning Res 2003;3:1157–1182.
   Google Scholar
• Darlington RB. Regression and Linear Models. McGraw-Hill Higher Edu., New York, 1990: 365–377.
   Google Scholar
• Hasegawa K, Kimura T, Funatsu K. GA strategy for variable selection in QSAR studies. Quant Struct Act Relat 1999;18:262–272.
   Google Scholar
• Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002;20:269–276.
   PubMed Web of Science ®Google Scholar
• Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis of steroids to carrier Proteins. J Am Chem Soc 1988;110:5959–5967.
   PubMed Web of Science ®Google Scholar
• Roy PP, Roy K. On some aspects of validation of predictive quantitative structure–activity relationship models. Expert Opin Drug Discov 2007;2:1567–1577.
   PubMed Web of Science ®Google Scholar
• Vighi M, Gramatica P, Consolaro F, Todeschini R. QSAR and chemometric approaches for setting water quality objectives for dangerous chemicals. Ecotoxicol Environ Saf 2001;49:206–220.
   PubMedGoogle Scholar
• Maggiora G. On outliers and activity cliffss-Why QSAR often disappoints. J Chem Inf Model 2006;46:1535–35.
   PubMed Web of Science ®Google Scholar